AR003459A1 - Forma iii cristalina de atorvastatina y sus hidratos y composiciones farmaceuticas con la misma. - Google Patents

Forma iii cristalina de atorvastatina y sus hidratos y composiciones farmaceuticas con la misma.

Info

Publication number
AR003459A1
AR003459A1 ARP960103600A AR10360096A AR003459A1 AR 003459 A1 AR003459 A1 AR 003459A1 AR P960103600 A ARP960103600 A AR P960103600A AR 10360096 A AR10360096 A AR 10360096A AR 003459 A1 AR003459 A1 AR 003459A1
Authority
AR
Argentina
Prior art keywords
form iii
atorvastatine
hydrates
same
pharmaceutical compositions
Prior art date
Application number
ARP960103600A
Other languages
English (en)
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21696090&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR003459(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of AR003459A1 publication Critical patent/AR003459A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Una forma cristalina nueva de hemisal de calcio de ácido [R-(R*,R*)-2-(4- fluorofenil)-Beta,Delta-dihidroxi-5-(1-metiletil)-3-fenil-4-[(fenilamino)carbonil]-1H-pirrol-1-heptanoico denominada Forma III caracterizada por la difracción decristal es finos de rayos X y/o resonancia magnética nucleardescripta en la memoria descriptiva así como los métodos para la elaboración y composición farmacéutica de la misma, que es útil como agente para tratar lahiperlipidemia ehipercolesterolemia.
ARP960103600A 1995-07-17 1996-07-16 Forma iii cristalina de atorvastatina y sus hidratos y composiciones farmaceuticas con la misma. AR003459A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US145295P 1995-07-17 1995-07-17

Publications (1)

Publication Number Publication Date
AR003459A1 true AR003459A1 (es) 1998-08-05

Family

ID=21696090

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP960103600A AR003459A1 (es) 1995-07-17 1996-07-16 Forma iii cristalina de atorvastatina y sus hidratos y composiciones farmaceuticas con la misma.
ARP960103598A AR003458A1 (es) 1995-07-17 1996-07-16 Forma cristalina de atorvastatina o hidrato de la misma y composicion farmaceutica que la comprende.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP960103598A AR003458A1 (es) 1995-07-17 1996-07-16 Forma cristalina de atorvastatina o hidrato de la misma y composicion farmaceutica que la comprende.

Country Status (38)

Country Link
US (1) US5969156A (es)
EP (2) EP0848705B1 (es)
JP (4) JP3296564B2 (es)
KR (2) KR100431038B1 (es)
CN (1) CN1087288C (es)
AR (2) AR003459A1 (es)
AT (3) ATE208375T1 (es)
AU (1) AU725424B2 (es)
BG (1) BG63630B1 (es)
BR (1) BR9609872A (es)
CA (1) CA2220018C (es)
CO (1) CO4700443A1 (es)
CY (1) CY2358B1 (es)
CZ (3) CZ294740B6 (es)
DE (2) DE69616808T2 (es)
DK (2) DK1148049T3 (es)
EA (1) EA000474B1 (es)
EE (1) EE03606B1 (es)
ES (2) ES2167587T3 (es)
GE (1) GEP20002029B (es)
HK (1) HK1018052A1 (es)
HR (1) HRP960339B1 (es)
HU (1) HU223599B1 (es)
IL (7) IL122118A (es)
MX (1) MX9709099A (es)
NO (1) NO309898B1 (es)
NZ (1) NZ312907A (es)
PE (1) PE1898A1 (es)
PL (1) PL193479B1 (es)
PT (2) PT1148049E (es)
RO (1) RO120070B1 (es)
SI (2) SI0848705T1 (es)
SK (1) SK284202B6 (es)
TW (1) TW486467B (es)
UA (1) UA51661C2 (es)
UY (2) UY24285A1 (es)
WO (1) WO1997003959A1 (es)
ZA (1) ZA966044B (es)

Families Citing this family (156)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
KR100431038B1 (ko) * 1995-07-17 2004-05-12 워너-램버트 캄파니 엘엘씨 결정질[ｒ-(ｒ*,ｒ*)]-2-(4-플루오로페닐)-베타,델타-디히드록시-5-(1-메틸에틸)-3-페닐-4-[(페닐아미노)카르보닐]-1ｈ-피롤-1-헵탄산 헤미 칼슘염 (아토르바스타틴)
HRP960312B1 (en) 1995-07-17 2001-10-31 Warner Lambert Co NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R*, R*)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1)
US6087511A (en) * 1996-07-16 2000-07-11 Warner-Lambert Company Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1)
US6569461B1 (en) 1999-03-08 2003-05-27 Merck & Co., Inc. Dihydroxy open-acid and salts of HMG-CoA reductase inhibitors
IN191236B (es) 1999-05-25 2003-10-11 Ranbaxy Lab Ltd
JP2003514798A (ja) * 1999-11-17 2003-04-22 テバ ファーマシューティカル インダストリーズ リミティド アトルバスタチンカルシウムの多形
US7411075B1 (en) 2000-11-16 2008-08-12 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
SI20425A (sl) 1999-12-10 2001-06-30 LEK tovarna farmacevtskih in kemi�nih izdelkov d.d. Priprava amorfnega atorvastatina
JP2003517038A (ja) * 1999-12-17 2003-05-20 ワーナー・ランバート・リサーチ・アンド・ディベロップメント・アイルランド・リミテッド 結晶質アトルバスタチン三水和物半カルシウム塩の工場規模での製造方法
IL149088A0 (en) 1999-12-17 2002-11-10 Warner Lambert Res & Dev Ie A process for producing crystalline atorvastatin calcium
GB0003305D0 (en) 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
US6258767B1 (en) * 2000-04-26 2001-07-10 Colgate-Palmolive Co. Spherical compacted unit dose softener
US6806290B2 (en) 2000-06-09 2004-10-19 Lek Pharmaceuticals D.D. Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same
SK16982002A3 (sk) 2000-06-09 2003-04-01 Lek Pharmaceuticals D. D. Stabilizovaná farmaceuticky účinná kompozícia a liečivý prípravok túto kompozíciu obsahujúci
SK6592003A3 (en) * 2000-11-03 2004-01-08 Teva Pharma Atorvastatin hemi-calcium form VII
US6777552B2 (en) 2001-08-16 2004-08-17 Teva Pharmaceutical Industries, Ltd. Processes for preparing calcium salt forms of statins
IL156055A0 (en) * 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
US7501450B2 (en) 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
ES2691680T3 (es) * 2000-12-18 2018-11-28 Cubist Pharmaceuticals Llc Daptomicina en forma cristalina y su preparación
US20060014674A1 (en) * 2000-12-18 2006-01-19 Dennis Keith Methods for preparing purified lipopeptides
CA2623599A1 (en) * 2000-12-27 2002-07-04 Paul Adrian Van Der Schaaf Crystalline forms of atorvastatin
EP1724256A3 (en) 2001-01-09 2007-03-21 Warner-Lambert Company LLC Novel process for the synthesis of 5-(4-fluorphenyl)-1-2(2-((2r,4r)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl)-2-isopropyl-4-phenyl-1h-pyrrole-3-carboxylic acid phenylamide
US6476235B2 (en) * 2001-01-09 2002-11-05 Warner-Lambert Company Process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide
AUPR255401A0 (en) * 2001-01-16 2001-02-08 Novogen Research Pty Ltd Regulation of lipids and/or bone density and compositions therefor
WO2002057229A1 (en) * 2001-01-19 2002-07-25 Biocon India Limited FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN)
SI20814A (sl) 2001-01-23 2002-08-31 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Priprava amorfnega atorvastatina
SI20848A (sl) * 2001-03-14 2002-10-31 Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. Farmacevtska formulacija, ki vsebuje atorvastatin kalcij
ES2558565T3 (es) * 2001-06-29 2016-02-05 Warner-Lambert Company Llc Formas cristalinas de sal de calcio del ácido [R-(R*,R*)]-2-(4-fluorofenil)-beta,delta-dihidroxi-5-(1-metiletil)-3-fenil-4-fenilamino)carbonil]-1H-pirrol-1-heptanoico (2:1) (atorvastatina)
ATE363917T1 (de) * 2001-07-19 2007-06-15 Pharmacia Corp Kombination von einem aldosterone rezeptor antagonisten und einem hmg coa reduktase hemmer
US7074818B2 (en) 2001-07-30 2006-07-11 Dr. Reddy's Laboratories Limited Crystalline forms VI and VII of Atorvastatin calcium
EE200400048A (et) * 2001-07-30 2004-04-15 Dr. Reddy's Laboratories Ltd. Atorvastatiinkaltsiumi kristalsed vormid VI ja VII
PE20030324A1 (es) * 2001-07-31 2003-04-03 Warner Lambert Co Composiciones farmaceuticas de amlodipina y atorvastatina
AU2002324715B2 (en) * 2001-08-16 2009-03-12 Teva Pharmaceutical Industries Ltd. Processes for preparing calcium salt forms of statins
US6569887B2 (en) * 2001-08-24 2003-05-27 Dov Pharmaceuticals Inc. (−)-1-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake
US20060173064A1 (en) * 2001-08-24 2006-08-03 Lippa Arnold S (-)-1-(3,4-Dichlorophenyl)-3-azabi cyclo[3.1.0]hexane, compositions thereof, and uses for treating alcohol-related disorders
HU227124B1 (en) * 2001-09-14 2010-07-28 Egis Gyogyszergyar Nyilvanosan Polymorphs of 1-pyrrole derivative, intermediate for the preparation of atorvastatin
US20060020137A1 (en) * 2001-11-29 2006-01-26 Limor Tessler Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
UA77990C2 (en) * 2001-12-12 2007-02-15 Crystalline calcium salt of (2:1) [r-(r*,r*)]-2-(4-fluorophenyl)-?,?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrroleheptanic acid
CZ296967B6 (cs) 2002-02-01 2006-08-16 Zentiva, A.S. Zpusob výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu)
EP1480950A4 (en) * 2002-02-15 2005-05-18 Teva Pharma NOVEL HEMI-CALCIUM CRYSTALLINE FORMS OF ATORVASTATIN AND METHODS FOR THEIR PREPARATION, AS WELL AS NEW METHODS FOR THE PREPARATION OF FORORVASTATIN HEMI-CALCIUM FORMS I, VIII AND IX
MXPA04007995A (es) * 2002-02-19 2004-11-26 Teva Pharma Desolvatacion de solvatos de hemicalcio de atorvastatina.
IL163666A0 (en) 2002-02-22 2005-12-18 New River Pharmaceuticals Inc Active agent delivery systems and methods for protecting and administering active agents
HUP0201083A2 (hu) * 2002-03-28 2004-06-28 Richter Gedeon Vegyészeti Gyár Rt. Új atorvastatinsók és az azokat tartalmazó gyógyszerkészítmények
ITMI20020907A1 (it) * 2002-04-29 2003-10-29 Chemi Spa Processo di preparazione della forma amorfa del sale di calcio della atorvastatina
US20080081834A1 (en) 2002-07-31 2008-04-03 Lippa Arnold S Methods and compositions employing bicifadine for treating disability or functional impairment associated with acute pain, chronic pain, or neuropathic disorders
ES2287549T3 (es) * 2002-08-06 2007-12-16 Warner-Lambert Company Llc Procedimiento para preparar la fenilamida del acido 5-(4-fluorofenil)-1-(2-((2r,4r)-4-hidroxi-6-oxo-tetrahidropiran-2-il)etil)-2-isopropil-4-fenil-1h-pirrol-3-carboxilico.
GB0218781D0 (en) * 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
JP2006503024A (ja) * 2002-09-03 2006-01-26 モレペン、ラボラトリーズ、リミテッド Ｖｉ型アトルバスタチンカルシウムまたはその水和物
US20060019269A1 (en) * 2002-10-17 2006-01-26 Decode Genetics, Inc. Susceptibility gene for myocardial infarction, stroke, and PAOD, methods of treatment
US20080293750A1 (en) * 2002-10-17 2008-11-27 Anna Helgadottir Susceptibility Gene for Myocardial Infarction, Stroke, Paod and Methods of Treatment
HRP20020885B1 (en) * 2002-11-11 2007-05-31 GlaxoSmithKline istra�iva�ki centar Zagreb d.o.o. SUBSTITUTED 9a-N-{N'-[4-(SULFONYL)PHENYLCARBAMOYL]}DERIVATIVES 9-DEOXO-9-DIHYDRO-9a-AZA-9a-HOMOERITHROMYCIN A AND 5-O-DESOZAMINYL-9-DEOXO-9-DIHYDRO-9a-AZA-9a-HOMOERITHRONOLIDE A
EP1572643A2 (en) * 2002-11-28 2005-09-14 Teva Pharmaceutical Industries Ltd. Crystalline form f of atorvastatin hemi-calcium salt
EP1424324A1 (en) * 2002-11-28 2004-06-02 Teva Pharmaceutical Industries Limited Crystalline form F of Atorvastatin hemi-calcium salt
EP1603554A1 (en) * 2003-03-17 2005-12-14 Japan Tobacco Inc. Method for increasing the oral bioavailability of s-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl]-2-methylpropanethioate
RS20050760A (sr) * 2003-04-14 2008-04-04 Warner-Lambert Company Llc., Postupak za izradu fenilamida 5-(4- fluorofenil)-1-(2-((2r, 4r)-4-hidroksi- 6-okso-tetrahidro-piran-2-il)etil)-2- izopropil-4-fenil-1h-pirol-3- karboksilne kiseline
TWI494102B (zh) * 2003-05-02 2015-08-01 Japan Tobacco Inc 包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合
US20040248972A1 (en) * 2003-05-16 2004-12-09 Ambit Biosciences Corporation Compounds and uses thereof
AU2004247627A1 (en) * 2003-05-16 2004-12-23 Ambit Biosciences Corporation Pyrrole compounds and uses thereof
US20050182125A1 (en) * 2003-05-16 2005-08-18 Ambit Biosciences Corporation Pyrrole compounds and uses thereof
US20040242670A1 (en) * 2003-06-02 2004-12-02 Sonny Sebastian Process for preparation of amorphous atorvastatin calcium
GB0312896D0 (en) 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
US7790197B2 (en) * 2003-06-09 2010-09-07 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
US20040253305A1 (en) * 2003-06-12 2004-12-16 Luner Paul E. Pharmaceutical compositions of atorvastatin
US20050271717A1 (en) * 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
US7655692B2 (en) 2003-06-12 2010-02-02 Pfizer Inc. Process for forming amorphous atorvastatin
UY28501A1 (es) 2003-09-10 2005-04-29 Astrazeneca Uk Ltd Compuestos químicos
AU2004272365A1 (en) * 2003-09-17 2005-03-24 Warner-Lambert Company Llc Crystalline forms of `R-(R*,R*))-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-`(phenylamino)carbonyl!-1H-pyrrole-1-heptanoic acid
GB0324791D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
BRPI0417138A (pt) * 2003-12-05 2007-02-21 Warner Lambert Co n-alquil-pirroles como inibidores de hmg-coa-redutase
EP1709008A1 (en) * 2004-01-19 2006-10-11 Ranbaxy Laboratories Limited Salts of hmg-coa reductase inhibitors and use thereof
CA2456430A1 (en) * 2004-01-28 2005-07-28 Brantford Chemicals Inc. Improved process for the preparation of amorphous atorvastatin calcium
US8158362B2 (en) * 2005-03-30 2012-04-17 Decode Genetics Ehf. Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype
US20100216863A1 (en) * 2004-01-30 2010-08-26 Decode Genetics Ehf. Susceptibility Gene for Myocardial Infarction, Stroke, and PAOD; Methods of Treatment
AU2005223491A1 (en) * 2004-03-17 2005-09-29 Ranbaxy Laboratories Limited Crystalline form of atorvastatin hemi calcium
CA2627940A1 (en) 2004-03-17 2005-10-06 Ranbaxy Laboratories Limited Process for the production of atorvastatin calcium in amorphous form
WO2005100313A1 (en) * 2004-04-16 2005-10-27 Pfizer Products Inc. Process for forming amorphous atorvastatin calcium
NZ550061A (en) * 2004-04-16 2009-05-31 Warner Lambert Co 7-[imidazol-1-yl]-3,5-dihydroxyheptanoic acids and lactone forms
ES2739493T3 (es) * 2004-05-05 2020-01-31 Pfizer Prod Inc Formas de sal de de atorvastatina con benetamina
CA2573969C (en) * 2004-07-16 2014-02-04 Lek Pharmaceuticals D.D. Oxidative degradation products of atorvastatin calcium
CA2701710C (en) 2004-07-20 2013-08-27 Warner-Lambert Company Llc Novel forms of [r-(r*,r*)]-2-(4-fluorophenyl)-.beta.,.delta.-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1)
CN101027282A (zh) * 2004-07-22 2007-08-29 特瓦制药工业有限公司 阿托伐他汀半钙的新晶形及其制备方法
US20070043100A1 (en) * 2005-08-16 2007-02-22 Hagen Eric J Novel polymorphs of azabicyclohexane
EP1784389A4 (en) 2004-08-27 2009-03-25 Biocon Ltd PROCESS FOR THE PREPARATION OF AMORPHIC ATORVASTATIN CALCIUM
KR100923939B1 (ko) * 2004-09-28 2009-10-29 테바 파마슈티컬 인더스트리즈 리미티드 실질적으로 불순물을 함유하지 않는 아토르바스타틴 칼슘의형태를 제조하는 방법
TW200630335A (en) 2004-10-18 2006-09-01 Teva Pharma Processes for preparing amorphous atorvastatin hemi-calcium
JP2008517992A (ja) 2004-10-28 2008-05-29 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー アモルファスのアトルバスタチンを形成する方法
WO2006048888A1 (en) * 2004-11-01 2006-05-11 Jubilant Organosys Limited Novel process for the preparation of amorphous atorvastatin calcium salt
WO2006048894A1 (en) * 2004-11-05 2006-05-11 Morepen Laboratories Limited Novel crystalline forms of atorvastatin calcium and processes for preparing them.
US20060100263A1 (en) * 2004-11-05 2006-05-11 Anthony Basile Antipyretic compositions and methods
WO2006054308A2 (en) 2004-11-22 2006-05-26 Dexcel Pharma Technologies Ltd. Stable atorvastatin formulations
CA2590533C (en) * 2004-11-23 2010-09-07 Warner-Lambert Company Llc 7-(2h-pyrazol-3-yl)-3,5-dihydroxy-heptanoic acid derivatives as hmg co-a reductase inhibitors for the treatment of lipidemia
CA2589537A1 (en) * 2004-12-02 2006-06-08 Stephen Craig Dyar Pharmaceutical compositions of amorphous atorvastatin and process for preparing same
WO2006059210A2 (en) * 2004-12-03 2006-06-08 Warner-Lambert Company Llc Fused bicyclic pyrrols as hmg-coa reductase inhibitors
EP1671947A1 (en) * 2004-12-20 2006-06-21 Ratiopharm GmbH Process for preparing pyrrole derivatives and intermediates
RO123642B1 (ro) * 2005-04-08 2015-07-30 Egis Gyogyszergyar Nyilvanosan Mukodo Reszvenytarsasag Procedeu pentru prepararea unei noi forme cristaline polimorfe a sării de hemicalciu a atorvastatinului
EP1919466B9 (en) 2005-07-11 2012-05-16 Cortria Corporation Formulations for treatment of lipoprotein abnormalities comprising a statin and a methylnicotinamide derivative
RU2008107336A (ru) 2005-07-27 2009-09-10 Дов Фармасьютикал, Инк. (Us) Новые 1-арил-з-азабицикло{3.1.0.} гексаны: получение и применение для лечения психоневрологических расстройств
US20070032665A1 (en) * 2005-08-04 2007-02-08 Srinivasulu Gudipati Preparation of atorvastatin calcium form i
WO2007020421A1 (en) 2005-08-15 2007-02-22 Arrow International Limited Crystalline and amorphous sodium atorvastatin
BRPI0614279A2 (pt) 2005-08-15 2012-11-06 Arrow Int Ltd atorvastatina sódica cristalina e amorfa
WO2007030302A2 (en) * 2005-09-01 2007-03-15 Prescient Medical, Inc. Drugs coated on a device to treat vulnerable plaque
CA2547216A1 (en) 2005-09-21 2007-03-21 Renuka D. Reddy Process for annealing amorphous atorvastatin
ES2304335T3 (es) 2005-11-21 2010-05-19 Warner-Lambert Company Llc Formas nuevas del acido (r-(r*,r*))-2-(4-fluorofenil)-b,b-dihidroxi-5-(1-metiletil)-3-fenil-4-((fenilamino)carbonil)1h-pirrol-1-heptanoico, de magnesio.
WO2007070667A2 (en) * 2005-12-13 2007-06-21 Teva Pharmaceutical Industries Ltd. Crystal form of atorvastatin hemi-calcium and processes for preparation thereof
EP1810667A1 (en) 2006-01-20 2007-07-25 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising amorphous atorvastatin
AU2007219107B2 (en) * 2006-02-22 2012-12-06 Mylan Laboratories Ltd. New crystalline form of Atorvastatin hemi-calcium
US20080045725A1 (en) * 2006-04-28 2008-02-21 Murry Jerry A Process For The Synthesis of (+) And (-)-1-(3,4-Dichlorophenyl)-3-Azabicyclo[3.1.0]Hexane
US20070265456A1 (en) * 2006-05-09 2007-11-15 Judith Aronhime Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
CA2654661C (en) 2006-06-26 2012-10-23 Amgen Inc. Compositions comprising modified lcat and use thereof for treating atherosclerosis
JP2008007507A (ja) * 2006-06-28 2008-01-17 Teva Pharmaceutical Industries Ltd 結晶形アトルバスタチン
KR20090083900A (ko) 2006-10-02 2009-08-04 코덱시스, 인코포레이티드 입체이성질체적으로 순수한 스타틴 및 이의 합성 중간체 제조용 조성물 및 제조 방법
US20080269348A1 (en) * 2006-11-07 2008-10-30 Phil Skolnick Novel Arylbicyclo[3.1.0]Hexylamines And Methods And Compositions For Their Preparation And Use
US8138377B2 (en) * 2006-11-07 2012-03-20 Dov Pharmaceutical, Inc. Arylbicyclo[3.1.0]hexylamines and methods and compositions for their preparation and use
US7834195B2 (en) 2007-01-24 2010-11-16 Apotex Pharmachem Inc. Atorvastatin calcium propylene glycol solvates
KR100878140B1 (ko) * 2007-01-29 2009-01-12 한미약품 주식회사 아토바스타틴의 스트론튬염 또는 이의 수화물, 및 이를포함하는 약학 조성물
PT103661B (pt) * 2007-02-23 2010-09-07 Hovione Farmaciencia S A Processo de preparação de minociclina base cristalina
JP2010520273A (ja) * 2007-03-02 2010-06-10 ドン・ア・ファーム・カンパニー・リミテッド ピロリルヘプタン酸誘導体の新規な結晶形態
US20080249141A1 (en) * 2007-04-06 2008-10-09 Palepu Nageswara R Co-therapy with and combinations of statins and 1,4-dihydropyridine-3,5-dicarboxydiesters
WO2008124122A1 (en) * 2007-04-09 2008-10-16 Scidose, Llc Combinations of statins and anti-obesity agent and glitazones
JP2010523659A (ja) * 2007-04-09 2010-07-15 サイドース・エルエルシー スタチン類と抗肥満症薬との組み合わせ
US9133159B2 (en) 2007-06-06 2015-09-15 Neurovance, Inc. 1-heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments
US20090069374A1 (en) * 2007-06-06 2009-03-12 Phil Skolnick Novel 1-Heteroaryl-3-Azabicyclo[3.1.0]Hexanes, Methods For Their Preparation And Their Use As Medicaments
US20110142883A1 (en) * 2007-07-20 2011-06-16 Actavis Group Ptc Ehf Amorphous Coprecipitates of Atorvastatin Pharmaceutically Acceptable Salts
EP2489730B1 (en) 2007-07-26 2015-12-30 Amgen, Inc Modified lecithin-cholesterol acyltransferase enzymes
NZ583607A (en) 2007-09-21 2012-06-29 Epiphany Biosciences Inc Valomaciclovir polymorphs
KR100813666B1 (ko) * 2007-10-23 2008-03-14 (주)에이에스텍 콜레스테롤 합성 저해제로서 아토르바스타틴의 프로드럭
DE102007052071A1 (de) 2007-10-30 2009-05-07 Stada Arzneimittel Ag Stabilisiertes Atorvastatin
US20090124817A1 (en) * 2007-11-09 2009-05-14 The Industry & Academic Cooperation In Chungnam National University Process for Preparing Amorphous Atorvastatin Calcium Nanoparticles
US20110064816A1 (en) * 2008-05-13 2011-03-17 Dr. Reddy's Laboratories Ltd. Atorvastatin compositions
US8115015B2 (en) * 2009-01-26 2012-02-14 Cadila Healthcare Limited Process for the preparation of amorphous atorvastatin calcium
US9388440B2 (en) 2009-04-01 2016-07-12 Mylan Laboratories Limited Enzymatic process for the preparation of (S)-5-(4-fluoro-phenyl)-5-hydroxy-1morpholin-4-yl-pentan-1-one, an intermediate of Ezetimibe and further conversion to Ezetimibe
CZ201039A3 (cs) 2010-01-19 2011-07-27 Zentiva, K. S Zpusob prumyslové výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu) s vysokým specifickým povrchem a jeho použití v lékové forme
HUP1000299A2 (hu) 2010-06-08 2012-02-28 Nanoform Cardiovascular Therapeutics Ltd Nanostrukturált Atorvastatint, gyógyszerészetileg elfogadott sóit és kokristályait tartalmazó készítmény és eljárás elõállításukra
KR20120011249A (ko) 2010-07-28 2012-02-07 주식회사 경보제약 아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법
WO2012027331A1 (en) 2010-08-27 2012-03-01 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
AU2011308911B2 (en) * 2010-09-30 2014-10-02 Wisconsin Alumni Research Foundation (20R,25S)-2-methylene-19,26-dinor-1alpha, 25-dihydroxyvitamin D3 in crystalline form
HU230737B1 (hu) 2010-11-16 2018-01-29 EGIS Gyógyszergyár Nyrt Eljárás rosuvastatin só előállítására
US20120165386A1 (en) * 2010-12-27 2012-06-28 Ranbaxy Laboratories Limited Stable oral pharmaceutial composition of atorvastatin
US9050342B2 (en) 2011-03-29 2015-06-09 Pfizer Inc. Beneficial effects of combination therapy on cholesterol
WO2013004591A1 (en) 2011-07-01 2013-01-10 Dsm Sinochem Pharmaceuticals Netherlands B.V. Micronized crystals of atorvastatin hemicalcium
IN2014CN04119A (es) 2011-11-15 2015-07-10 Reddys Lab Ltd Dr
JP6635655B2 (ja) 2011-12-08 2020-01-29 アムジエン・インコーポレーテツド ヒトｌｃａｔ抗原結合タンパク質および治療法におけるそれらの使用
EP2844245A1 (en) * 2012-04-30 2015-03-11 F. Hoffmann-La Roche AG New formulation
CN103483238B (zh) * 2013-08-20 2014-12-31 蚌埠丰原医药科技发展有限公司 阿托伐他汀钙三水合物的制备方法
CA2958898A1 (en) 2014-09-15 2016-03-24 The Board Of Trustees Of The Leland Stanford Junior University Targeting aneurysm disease by modulating phagocytosis pathways
EP3811972B1 (en) 2015-02-27 2023-01-11 The Board of Trustees of the Leland Stanford Junior University Combination therapy for treatment of atherosclerosis
CN104945300B (zh) * 2015-06-17 2017-05-10 北京嘉林药业股份有限公司 一种ⅰ型阿托伐他汀钙的纯化方法
EP3184103A1 (en) 2015-12-21 2017-06-28 Hexal AG Pharmaceutical composition comprising atorvastatin or a salt thereof
US10600502B2 (en) 2016-12-20 2020-03-24 Astrazeneca Uk Ltd. Systems and methods for dispensing a statin medication over the counter
KR101723783B1 (ko) 2017-02-24 2017-04-07 주식회사 경보제약 아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법
EP3501502A1 (en) 2017-12-20 2019-06-26 Midas Pharma GmbH Fixed dosed pharmaceutical compositions comprising amlodipine, ramipril and atorvastatin
CN108558726A (zh) * 2018-03-14 2018-09-21 湖北广济药业股份有限公司 一种高纯度阿托伐他汀钙的制备方法
CN110776451B (zh) * 2020-01-02 2020-05-22 湖南迪诺制药股份有限公司 一种i晶型阿托伐他汀钙的制备方法
KR20210001641U (ko) 2020-01-08 2021-07-16 주식회사 다마가산업 최소구성의 초저가 콘크리트 타설 레벨표시구
EP4052695A1 (en) 2021-03-05 2022-09-07 Midas Pharma GmbH Stable oral fixed-dose immediate release pharmaceutical compositions comprising amlodipine, atorvastatin and candesartan cilexetil

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4456753A (en) 1983-02-07 1984-06-26 Pfizer Inc. Process for the manufacture of highly crystalline sodium cefoperazone
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5316765A (en) * 1989-09-07 1994-05-31 Karl Folkers Foundation For Biomedical And Clinical Research Use of coenzyme Q10 in combination with HMG-CoA reductase inhibitor therapies
JP3528186B2 (ja) 1991-06-24 2004-05-17 日産化学工業株式会社 光学活性キノリンメバロン酸のジアステレオマー塩
DE4235133A1 (de) 1992-10-19 1994-04-21 Bayer Ag Kristallines (R)-(-)-2-Cycloheptyl-N-methylsulfonyl-[4-(2-chinolinyl-methoxy)-phenyl]-acetamid
ES2133158T3 (es) * 1993-01-19 1999-09-01 Warner Lambert Co Formulacion ci-981 oral, estable y proceso de preparacion del mismo.
JP3623531B2 (ja) 1993-06-07 2005-02-23 ビーエーエスエフ アクチェンゲゼルシャフト 結晶質ｌ−アスコルビン酸−２−燐酸エステルマグネシウム塩の製造法
KR100431038B1 (ko) * 1995-07-17 2004-05-12 워너-램버트 캄파니 엘엘씨 결정질[ｒ-(ｒ*,ｒ*)]-2-(4-플루오로페닐)-베타,델타-디히드록시-5-(1-메틸에틸)-3-페닐-4-[(페닐아미노)카르보닐]-1ｈ-피롤-1-헵탄산 헤미 칼슘염 (아토르바스타틴)
HRP960313B1 (en) 1995-07-17 2002-08-31 Warner Lambert Co Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)
JP2003517038A (ja) 1999-12-17 2003-05-20 ワーナー・ランバート・リサーチ・アンド・ディベロップメント・アイルランド・リミテッド 結晶質アトルバスタチン三水和物半カルシウム塩の工場規模での製造方法
IL149088A0 (en) 1999-12-17 2002-11-10 Warner Lambert Res & Dev Ie A process for producing crystalline atorvastatin calcium
ES2558565T3 (es) 2001-06-29 2016-02-05 Warner-Lambert Company Llc Formas cristalinas de sal de calcio del ácido [R-(R*,R*)]-2-(4-fluorofenil)-beta,delta-dihidroxi-5-(1-metiletil)-3-fenil-4-fenilamino)carbonil]-1H-pirrol-1-heptanoico (2:1) (atorvastatina)

Also Published As

Publication number Publication date
SK6298A3 (en) 1998-10-07
IL128862A0 (en) 2000-01-31
AR003458A1 (es) 1998-08-05
DK1148049T3 (da) 2005-03-29
EE9800015A (et) 1998-08-17
NO980207L (no) 1998-01-16
PT848705E (pt) 2002-02-28
HK1018052A1 (en) 1999-12-10
CY2358B1 (en) 2004-06-04
MX9709099A (es) 1998-02-28
TW486467B (en) 2002-05-11
WO1997003959A1 (en) 1997-02-06
IL128862A (en) 2007-12-03
ATE208375T1 (de) 2001-11-15
EE03606B1 (et) 2002-02-15
PL193479B1 (pl) 2007-02-28
ES2167587T3 (es) 2002-05-16
RO120070B1 (ro) 2005-08-30
HUP9900678A3 (en) 2000-04-28
DK0848705T3 (da) 2002-02-04
IL203847A0 (en) 2011-08-01
CO4700443A1 (es) 1998-12-29
SI0848705T1 (en) 2002-04-30
NO980207D0 (no) 1998-01-16
CZ294740B6 (cs) 2005-03-16
EP0848705A1 (en) 1998-06-24
CZ12198A3 (cs) 1998-10-14
HU223599B1 (hu) 2004-10-28
HUP9900678A2 (hu) 1999-07-28
CN1190955A (zh) 1998-08-19
DE69616808D1 (en) 2001-12-13
JP2003073353A (ja) 2003-03-12
JP2014051533A (ja) 2014-03-20
ES2233526T3 (es) 2005-06-16
CZ294695B6 (cs) 2005-02-16
CA2220018C (en) 2001-04-17
GEP20002029B (en) 2000-04-10
AT8453U1 (de) 2006-08-15
CZ294108B6 (cs) 2004-10-13
KR19990029043A (ko) 1999-04-15
EP0848705B1 (en) 2001-11-07
PT1148049E (pt) 2005-02-28
DE69616808T2 (de) 2002-05-29
IL122118A0 (en) 1998-04-05
NZ312907A (en) 2000-12-22
CA2220018A1 (en) 1997-02-06
IL122118A (en) 1999-07-14
US5969156A (en) 1999-10-19
SI1148049T1 (en) 2005-02-28
AU725424B2 (en) 2000-10-12
IL177376A0 (en) 2006-12-10
JP3296564B2 (ja) 2002-07-02
UY24285A1 (es) 1997-01-17
EA199800130A1 (ru) 1998-08-27
PE1898A1 (es) 1998-03-04
PL324496A1 (en) 1998-05-25
BG102187A (en) 1998-10-30
AU6484296A (en) 1997-02-18
KR20030097628A (ko) 2003-12-31
IL128864A (en) 2007-10-31
DE69634054D1 (de) 2005-01-20
KR100389518B1 (ko) 2003-11-15
IL177377A0 (en) 2006-12-10
BR9609872A (pt) 1999-03-23
ATE284868T1 (de) 2005-01-15
EA000474B1 (ru) 1999-08-26
JP4790194B2 (ja) 2011-10-12
IL128865A (en) 2006-04-10
IL128865A0 (en) 2000-01-31
SK284202B6 (sk) 2004-10-05
EP1148049B1 (en) 2004-12-15
CN1087288C (zh) 2002-07-10
JPH11509230A (ja) 1999-08-17
UA51661C2 (uk) 2002-12-16
ZA966044B (en) 1997-02-03
KR100431038B1 (ko) 2004-05-12
UY24985A1 (es) 2001-03-16
BG63630B1 (bg) 2002-07-31
DE69634054T2 (de) 2005-12-08
JP2011195592A (ja) 2011-10-06
IL128864A0 (en) 2000-01-31
HRP960339A2 (en) 1998-04-30
NO309898B1 (no) 2001-04-17
EP1148049A1 (en) 2001-10-24
HRP960339B1 (en) 2002-06-30

Similar Documents

Publication Publication Date Title
AR003459A1 (es) Forma iii cristalina de atorvastatina y sus hidratos y composiciones farmaceuticas con la misma.
BR9610567A (pt) Hemi sal cálcio de ácido (R(R*,R*)-2-(4-fluorofenil)-beta-delta-dihidróxi-5-(1-metil-etil)-3-fenil-4-((fenilamino)carbonil)-1H-pirrol-1-heptanóico(atorvastatína) de forma cristalina iii
EA200301243A1 (ru) Кристаллические формы [r-(r*,r*)]-2-(4-фторфенил)-бета, дельта-дигидрокси-5-(1-метилэтил)-3-фенил-4-[(фениламино) карбонил]-1h-пиррол-1-гептановой кислоты кальциевой соли (2:1) (аторвастатин)
ECSP961824A (es) Forma iii cristalina de sal de calcio de acido [r-(r*,r*)- 2-(4 fluorofenil) - b, g- dihidroxi-5-(1 metiletil) - 3- fenil - 4-[(fenilamino) carbonil]- 1h -pirrol - 1- heptanoico (2.1)
AR045654A1 (es) Formas cristalinas de acido r-(r*,r*)-2-(4- fluorofenil) - , dihidroxi - 5-(1- metiletil)- 3- fenil- 4-( fenilamino) - carbonil- 1h- pirrol-1- heptanoico
CA2521833A1 (en) Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1) (atorvastatin)

Legal Events

Date Code Title Description
FC Refusal